GlassScriptPhysician profile
Jeffrey H Etherton
NPI 1144212366
$10,557.46
in general payments reported to CMS, 2019-2025
33 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,058 · 2020: $987 · 2021: $1,556 · 2022: $1,397 · 2023: $1,400 · 2024: $1,937 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,542 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,542.12 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,732.63 | 2021-2025 | Selectsecure, Cobalt Dr Mri Surescan, Mycarelink |
| Abbott Laboratories | $1,630.08 | 2019-2025 | Nc Trek Neo, Xience Skypoint, Assurity |
| Medtronic Vascular, INC. | $1,562.40 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,162.93 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $686.38 | 2019-2024 | Brilinta, Farxiga |
| Amgen INC. | $484.22 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $454.81 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $332.76 | 2019-2025 | Camzyos, Eliquis |
| Siemens Medical Solutions USA, INC. | $317.87 | 2021 | |
| Boston Scientific Corporation | $303.54 | 2019-2024 | Watchman, Ekosonic |
| Novartis Pharmaceuticals Corporation | $285.41 | 2019-2025 | |
| Terumo Medical Corporation | $247.05 | 2020-2025 | Metacross Otw, Glidewire |
| Scpharmaceuticals INC. | $235.82 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.83 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $150.17 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $139.49 | 2025 | Sapien 3 Ultra Resilia |
| Abiomed | $113.91 | 2020 | |
| Irhythm Technologies, INC. | $106.53 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Chiesi USA, INC. | $82.42 | 2021 | |
| Janssen Pharmaceuticals, INC | $78.48 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $39.49 | 2019-2025 | Evkeeza |
| Acist Medical Systems, INC. | $32.81 | 2024 | |
| Merck Sharp & Dohme LLC | $29.03 | 2022-2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $27.82 | 2019 | |
| Cardinal Health 200 LLC | $21.20 | 2021 | |
| Kestra Medical Technology Services, INC. | $21.02 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $20.41 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $19.87 | 2022 | |
| Elutia, INC. | $19.17 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.36 | 2025 | |
| Bard Peripheral Vascular, INC. | $15.64 | 2020 | |
| Heartflow, INC. | $14.51 | 2024 | |
| Amarin Pharma, INC. | $14.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Etherton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.